Delving into the Latest Updates on KNT-0916 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

KNT-0916

Target

FGFR2

Action

antagonists

Mechanism

FGFR2 antagonists(Fibroblast growth factor receptor 2 antagonists)

Therapeutic Areas

Neoplasms

Active Indication

Solid tumorFGFR2 Mutation Solid Tumors

Inactive Indication-

Originator Organization

KinoTeck Therapeutics Co., Ltd

Active Organization

KinoTeck Therapeutics Co., Ltd

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

This is a Phase1, open-label, dose escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of KNT-0916 in patients with unresectable or metastatic solid tumors harboring FGFR2 alterations who have failed prior systemic therapy. This study is divided into 2 parts, dose escalation part(part A), dose expansion part(partB).

Start Date31 Mar 2025

Sponsor / Collaborator

KinoTeck Therapeutics Co., Ltd

CTR20250595

/ RecruitingPhase 1

一项评价KNT-0916片在FGFR2异常不可切除的局部晚期或转移性实体瘤患者中的安全性、耐受性、药代动力学和初步疗效的单臂、开放、剂量递增和扩展的I期临床研究

[Translation] A single-arm, open-label, dose-escalation and expansion phase I clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of KNT-0916 tablets in patients with unresectable locally advanced or metastatic solid tumors with FGFR2 abnormalities

评估KNT-0916在FGFR2异常不可切除的局部晚期或转移性实体瘤患者中的安全性、耐受性和疗效。

[Translation]

To evaluate the safety, tolerability, and efficacy of KNT-0916 in patients with unresectable locally advanced or metastatic solid tumors with FGFR2 abnormalities.

Start Date26 Mar 2025

Sponsor / Collaborator

KinoTeck Therapeutics Co., Ltd

100 Clinical Results associated with KNT-0916

Login to view more data

100 Translational Medicine associated with KNT-0916

Login to view more data

100 Patents (Medical) associated with KNT-0916

Login to view more data

100 Deals associated with KNT-0916

Login to view more data